KR0130906B1 - 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 - Google Patents

면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Info

Publication number
KR0130906B1
KR0130906B1 KR1019880002464A KR880002464A KR0130906B1 KR 0130906 B1 KR0130906 B1 KR 0130906B1 KR 1019880002464 A KR1019880002464 A KR 1019880002464A KR 880002464 A KR880002464 A KR 880002464A KR 0130906 B1 KR0130906 B1 KR 0130906B1
Authority
KR
South Korea
Prior art keywords
ida
tumor
antibody
cells
mice
Prior art date
Application number
KR1019880002464A
Other languages
English (en)
Korean (ko)
Other versions
KR880010775A (ko
Inventor
화큐하르 캠프벨 맥켄지 아이언
알란 피터즈 지오프레이
존 스미드 마크
Original Assignee
팜이탈리아 카를로 에르바 에스. 알. 엘.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 팜이탈리아 카를로 에르바 에스. 알. 엘. filed Critical 팜이탈리아 카를로 에르바 에스. 알. 엘.
Publication of KR880010775A publication Critical patent/KR880010775A/ko
Application granted granted Critical
Publication of KR0130906B1 publication Critical patent/KR0130906B1/ko

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019880002464A 1987-03-11 1988-03-10 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물 KR0130906B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AUPI0803 1987-03-11
AUPI080387 1987-03-11
AUPI295587 1987-07-07
AUPI2955 1987-07-07

Publications (2)

Publication Number Publication Date
KR880010775A KR880010775A (ko) 1988-10-24
KR0130906B1 true KR0130906B1 (ko) 1998-04-23

Family

ID=25643244

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880002464A KR0130906B1 (ko) 1987-03-11 1988-03-10 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물

Country Status (29)

Country Link
US (1) US5798097A ( )
JP (1) JP2736255B2 ( )
KR (1) KR0130906B1 ( )
CN (1) CN1045621C ( )
AT (1) AT395375B ( )
AU (1) AU622105B2 ( )
BE (1) BE1001051A4 ( )
CA (1) CA1329156C ( )
CH (1) CH678815A5 ( )
CZ (1) CZ161288A3 ( )
DE (1) DE3808166C2 ( )
DK (1) DK173792B1 ( )
ES (1) ES2006109A6 ( )
FI (1) FI98706C ( )
FR (1) FR2612074B1 ( )
GB (1) GB2203154B ( )
GR (1) GR1000059B ( )
HU (1) HU205266B ( )
IE (1) IE64781B1 ( )
IL (1) IL85688A0 ( )
IT (1) IT8819746A0 ( )
MY (1) MY103231A ( )
NL (1) NL8800610A ( )
NO (1) NO178954C ( )
NZ (1) NZ223834A ( )
PT (1) PT86960B ( )
RU (1) RU2106147C1 ( )
SE (1) SE503402C2 ( )
YU (1) YU46858B ( )

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ATE489108T1 (de) * 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
WO2002049672A2 (en) * 2000-12-21 2002-06-27 Mcgill University Conjugates of antibodies and anticancer drugs
ATE359300T1 (de) * 2001-01-19 2007-05-15 Ludwig Inst Cancer Res Flt4 (vegfr-3) als ein ziel für krebs darstellung und anti-krebs-behandlung
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0511266D0 (en) * 2005-06-02 2005-07-13 Trust Chemical compounds
US20080108138A1 (en) * 2006-06-13 2008-05-08 Vermette Patrick Bioactive compositions and their use in cell patterning
EP2646470B1 (en) 2010-11-30 2017-03-01 F. Hoffmann-La Roche AG Low affinity anti-transferrin receptor antibodies and their use to transfer therapeutic scfv across the blood brain barrier
PT2956476T (pt) 2013-02-18 2020-02-21 Vegenics Pty Ltd Moléculas de ligação e usos destas

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT346838B (de) * 1975-01-22 1978-11-27 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
GB1500421A (en) * 1975-01-22 1978-02-08 Farmaceutici Italia Optically active anthracyclinones
AT343812B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven daunosaminylderivaten von anthracyclinonen
AT343811B (de) * 1975-01-22 1978-06-26 Farmaceutici Italia Verfahren zur herstellung von neuen optisch aktiven anthracyclinonen
GB1511680A (en) 1975-11-18 1978-05-24 Farmaceutici Italia Daunosaminyl anthracyclinones
GB1541436A (en) * 1976-02-02 1979-02-28 Searle & Co Immunological materials
US5162512A (en) * 1982-03-09 1992-11-10 Cytogen Corporation Amine derivatives of anthracycline antibodies
US4867973A (en) * 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US4950738A (en) * 1984-09-13 1990-08-21 Cytogen Corporation Amine derivatives of anthracycline antibiotics
JPS59186924A (ja) * 1983-04-08 1984-10-23 Kureha Chem Ind Co Ltd ヒト免疫グロブリン結合抗腫瘍剤
US4545985A (en) 1984-01-26 1985-10-08 The United States Of America As Represented By The Secretary, Dept. Of Health And Human Services Pseudomonas exotoxin conjugate immunotoxins
GB8413464D0 (en) * 1984-05-25 1984-07-04 Erba Farmitalia Anthracycline-anionic polymer conjugates
JPS61155334A (ja) * 1984-12-28 1986-07-15 Teijin Ltd 殺細胞性修飾免疫グロブリン及びその製造方法
FR2584293B1 (fr) * 1985-07-04 1989-03-17 Ire Celltarg Sa Anticorps utiles comme agents de pilotage et conjugues les incorporant

Also Published As

Publication number Publication date
YU48288A (en) 1989-08-31
CH678815A5 ( ) 1991-11-15
FR2612074B1 (fr) 1991-06-21
SE8800886D0 (sv) 1988-03-11
NZ223834A (en) 1990-05-28
CN88101810A (zh) 1988-11-09
DE3808166A1 (de) 1988-09-22
DK131588A (da) 1988-09-12
SE8800886L (sv) 1989-09-12
DK131588D0 (da) 1988-03-11
NO178954C (no) 1996-07-10
FI881158A0 (fi) 1988-03-11
PT86960B (pt) 1992-06-30
CN1045621C (zh) 1999-10-13
NL195078C ( ) 2003-07-30
NO881105L (no) 1988-09-12
AU1288188A (en) 1988-09-15
GR1000059B (el) 1990-06-27
FI881158A (fi) 1988-09-12
GB2203154B (en) 1991-06-26
BE1001051A4 (fr) 1989-06-20
FR2612074A1 (fr) 1988-09-16
GB8805865D0 (en) 1988-04-13
DK173792B1 (da) 2001-11-05
CZ281193B6 (cs) 1996-07-17
ES2006109A6 (es) 1989-04-01
NO881105D0 (no) 1988-03-11
IE880701L (en) 1988-09-11
YU46858B (sh) 1994-06-24
DE3808166C2 (de) 1997-08-28
JPS63301832A (ja) 1988-12-08
GB2203154A (en) 1988-10-12
NO178954B (no) 1996-04-01
FI98706C (fi) 1997-08-11
HU205266B (en) 1992-04-28
KR880010775A (ko) 1988-10-24
HUT46547A (en) 1988-11-28
PT86960A (pt) 1988-04-01
NL8800610A (nl) 1988-10-03
AU622105B2 (en) 1992-04-02
AT395375B (de) 1992-12-10
IL85688A0 (en) 1988-08-31
RU2106147C1 (ru) 1998-03-10
IE64781B1 (en) 1995-09-06
ATA67488A (de) 1992-05-15
CZ161288A3 (en) 1996-07-17
JP2736255B2 (ja) 1998-04-02
GR880100148A (en) 1989-01-31
IT8819746A0 (it) 1988-03-11
CA1329156C (en) 1994-05-03
FI98706B (fi) 1997-04-30
SE503402C2 (sv) 1996-06-10
US5798097A (en) 1998-08-25
MY103231A (en) 1993-05-29

Similar Documents

Publication Publication Date Title
US5556623A (en) Antibody-drug conjugates
CA1222694A (en) Immunochemotherapy for malignant tumors, particularly pancreatic cancer
Smyth et al. Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies
WO2017012591A1 (en) Complex comprising metallic nanoparticle, linkers and antibodies
US5514794A (en) Antibody-drug conjugates
Smyth et al. Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies
KR0130906B1 (ko) 면역글로불린 결합체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
Pietersz et al. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates
EP0248040B1 (en) Ricin-antibody conjugates
Kanellos et al. Anti‐tumour activity of aminopterin‐monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate‐monoclonal antibody conjugates
Goerlach et al. In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates
EP0485749A2 (en) Chemical modification of antibodies for creating of immunoconjugates
Smyth et al. The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab') 2 conjugates
JPS6069034A (ja) 免疫毒素、免疫毒素を含有する薬剤及び免疫毒素の生体外使用方法
RU2009500C1 (ru) Способ получения цитотоксического коньюгата
US20080095802A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients iwth transplanted organs, B) as radiosensitizers to cancer cells in paients undergoing radiation therapy, and C) in vitaminpbinding proteins as drug carriers in the diagnosis and treatment of cancer
Arnon et al. Complexes and conjugates of cis-Pt for Immunotargeted Chemotherapy
WO2002000170A2 (en) Targeted delivery of cytotoxic drugs a) to activated lymphocytes in patients with transplanted organs, b) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and c) in vitamin-binding proteins as drug carriers in the diagnosis and treatment of cancer
AU2007201744A1 (en) Targeted delivery of cytotoxic drugs A) to activated lymphocytes in patients with transplanted organs, B) as radiosensitizers to cancer cells in patients undergoing radiation therapy, and C) in vitamin binding proteins as drug carriers in the diagnosis and treatment of cancer
WO1992014758A1 (en) Conjugate molecules

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E601 Decision to refuse application
J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

Free format text: TRIAL NUMBER: 1996201001948; APPEAL AGAINST DECISION TO DECLINE REFUSAL

N231 Notification of change of applicant
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20101029

Year of fee payment: 14

LAPS Lapse due to unpaid annual fee